CancerDrs

Endometrial Cancer clinical trials in Nevada

14 actively recruiting endometrial cancer trials at 2 sites across Nevada.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Sites in Nevada:
  • OptumCare Cancer Care at Charleston — Las Vegas, Nevada
  • Women's Cancer Center of Nevada — Las Vegas, Nevada
  • OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response …

Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT05611931
Sites in Nevada:
  • Women's Cancer Center of Nevada — Las Vegas, Nevada
  • Center Of Hope — Reno, Nevada
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…

Sponsor: AstraZeneca
NCT ID: NCT06989112
Sites in Nevada:
  • Research Site — Las Vegas, Nevada
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…

Sponsor: NRG Oncology
NCT ID: NCT05646316
Sites in Nevada:
  • Women's Cancer Center of Nevada — Las Vegas, Nevada
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part…

Sponsor: Kartos Therapeutics, Inc.
NCT ID: NCT05797831
Sites in Nevada:
  • Women's Cancer Center of Nevada — Las Vegas, Nevada
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how…

Sponsor: BioNTech SE
NCT ID: NCT06340568
Sites in Nevada:
  • The Center of Hope Reno — Reno, Nevada
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Nevada:
  • OptumCare Cancer Care at Charleston — Las Vegas, Nevada
  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation — Las Vegas, Nevada
  • Summerlin Hospital Medical Center — Las Vegas, Nevada
  • OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
  • Renown Regional Medical Center — Reno, Nevada
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Nevada:
  • OptumCare Cancer Care at Charleston — Las Vegas, Nevada
  • OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Nevada:
  • Women's Cancer Center of Nevada — Las Vegas, Nevada
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/R…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05640999
Sites in Nevada:
  • Womens Cancer Center of Nevada — Las Vegas, Nevada
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25